Head to Head Comparison: Repligen (RGEN) versus Its Competitors

Repligen (NASDAQ:RGEN) is one of 109 publicly-traded companies in the “Life Sciences Tools & Services” industry, but how does it weigh in compared to its competitors? We will compare Repligen to related businesses based on the strength of its valuation, institutional ownership, analyst recommendations, risk, earnings, profitability and dividends.

Insider and Institutional Ownership

97.6% of Repligen shares are owned by institutional investors. Comparatively, 54.0% of shares of all “Life Sciences Tools & Services” companies are owned by institutional investors. 0.6% of Repligen shares are owned by company insiders. Comparatively, 14.8% of shares of all “Life Sciences Tools & Services” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Repligen and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Repligen	$738.26 million	$48.89 million	-822.00
Repligen Competitors	$2.25 billion	$55.11 billion	-7.77

Repligen’s competitors have higher revenue and earnings than Repligen. Repligen is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Repligen and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repligen	1	3	12	2	2.83
Repligen Competitors	957	3186	5518	178	2.50

Repligen presently has a consensus price target of $178.57, suggesting a potential upside of 3.45%. As a group, “Life Sciences Tools & Services” companies have a potential downside of 1.89%. Given Repligen’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Repligen is more favorable than its competitors.

Risk & Volatility

Repligen has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Repligen’s competitors have a beta of 0.94, indicating that their average stock price is 6% less volatile than the S&P 500.

Profitability

This table compares Repligen and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Repligen	-1.47%	5.49%	3.93%
Repligen Competitors	-538.84%	77.19%	-13.52%

Summary

Repligen beats its competitors on 8 of the 13 factors compared.

Repligen Company Profile

Repligen is a life sciences company that develops and supplies technologies used in the manufacture of biologic medicines. Its products support biopharmaceutical companies and contract manufacturers in producing treatments such as monoclonal antibodies, vaccines and gene therapies. The company’s offerings span several stages of bioprocessing, including filtration, chromatography, fluid management and process analytics. Its products include filtration systems and single-use components, chromatography solutions and instruments that help monitor and control manufacturing processes.